This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
We stained 13 primary CNS lymphomas (PCNSLs) (six from patients with AIDS, seven from immunocompetent patients) with a panel of antibodies to T cells (pan T cell [CD3], T helper cell [CD4], T suppressor cell [CD8], delta/Delta cell [CD4minus 8minus]), B cells (CD20), hematopoietic cells (T200), and NK cell (CD56).We estimated the percentage of tumor cells staining with each antibody. All tumors were B-cell lymphomas. The non-AIDS tumors showed a significant infiltration with CD3plus cells (mean of 10.82% of total cells). The AIDS patients' tumors showed a smaller percentage of CD3plus infiltrating cells (mean, 4 88% of total cells) (p less than 0.01) CD4plus cells were 9.11% of the total hematopoietic cells in the non-AIDS patients and 3.13% in AIDS patients (p less than 0.01). AIDS patients showed some CD8plus cells (0.3%), which was significantly higher than in immunocompetent patients (0%) (p less than 0.05). Very few tumor cells stained with the NK cell and delta/Delta cell markers. Both immunocompetent and AIDS patients with PCNSL exhibit significant CD3plus and CD4plus cell infiltration of their tumors, this infiltration is significantly lower in AIDS patients. AIDS patients show a minor CD8plus cell infiltration of their tumors. These results on PCNSL are different from systemic lymphomas, which show a higher CD4 and CD8 cell infiltration, and may offer insights into the more aggressive nature of AIDS-related PCNSL.
NEUROLOGY 1996;46: 440-444
- Copyright 1996 by the Advanstar Communication Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
